Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
How Do We Convert That Into a Drug?
When I stepped in, what I did know about the technology was that you could deliver a synthetic oligo at that point in time, partially modified into a mouse. But because it's partially modified, it died very quickly and had a very, very short half-life,. but you could get 70, 80% editing in vitro. Now the challenge was, how do you take a system that you know works and start building it towards making a drug? And that usually is a couple of logs in terms of difficulty going from a proof of concept to something that's very, very meaningful. The good thing for us is that over the last two decades, the toolbox, both on delivery as
Transcript
Play full episode
